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ABSTRACT: Lung transplant recipients (LTxRs) with acute rejection (AR) and chronic rejection (bronchiolitis obliterans
syndrome [BOS]) induce circulating exosomes known to contain donor human leukocyte antigens and lung-associated self-antigens.
Here, we sought to identify proteomic signatures in circulating extracellular vesicles (EVs) that differentiate LTxRs in 4 groups:
stable, AR, BOS, or respiratory viral infection (RVI). EVs were isolated from plasma from patients in each group via
ultracentrifugation. EV protein cargoes were prepared for shotgun proteomics using liquid chromatography−tandem mass
spectrometry. We identified 2 unique proteins for AR, 4 for RVI, 24 for BOS, and 8 for stable LTxRs. Differential analysis of AR,
BOS, RVI, and stable proteins identified significantly deregulated proteins (p < 0.05, log2(fold change) > ±1) in each condition (31,
2, and 2, respectively). EVs from LTxRs with AR contained proteins involved in immunoglobulin, complement regulation,
coagulation, and innate and adaptive immune response pathways. EVs from LTxRs with BOS revealed enriched immunoglobulin
receptors and a carboxypeptidase N catalytic chain. EVs from LTxRs with RVI had an enriched macrophage-stimulating factor. We
found unique signatures in LTxRs with AR, BOS, and RVI, highlighting complex immune mechanisms underlying lung allograft
rejection. Proteomic signatures in LTxRs’ circulating EVs provided insights into immunological mechanisms of graft rejection and
RVI.
1. INTRODUCTION
Lung transplantation (LTx) is a treatment option for patients
with end-stage respiratory disease such as idiopathic
pulmonary fibrosis, chronic obstructive pulmonary disease,
cystic fibrosis, and other interstitial lung disease.1 Despite
immunosuppressive measures, post-LTx recovery can be
challenged by acute rejection (AR) or chronic rejection. The
median survival after LTx is just 5.8 years, and this is the
shortest survival compared with all other solid organ
transplants, results primarily from chronic rejection.2 Several
risk factors for AR or chronic rejection have been proposed,
including immune responses to human leukocyte antigen
(HLA), development of donor-specific antibody (DSA) against
HLA, immune response to lung-associated self-antigens
(SAgs), and respiratory viral infection (RVI).3−5 The
contribution and interplay of factors underlying each of these
mechanisms in modulating the immune responses of LTx
recipients (LTxRs) has not been fully characterized.6
Extracellular vesicles (EVs) play an important role in
defining the immunopathogenesis of lung disease.7 EVs are a
family of particles released by cells, and they are involved in
various physiological functions. EVs vary in size, morphology,
and content and are classified based on the mechanism of their
release. Exosomes, which are membrane-bound EVs, result
from the fusion of late endosomes with the plasma membrane
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(<200 nm in diameter), whereas microvesicles and apoptotic
bodies (typically 200−1000 nm in diameter) are the result of
vertical trafficking of molecules to the plasma membrane,
where molecules are shed in the form of EVs into the
extracellular space. Several reports demonstrated that EVs
carry a diverse cargo of proteins, lipids, metabolites, and RNAs
(mRNAs and noncoding RNAs, including microRNAs).8 EVs
have also been shown to contribute to intercellular
communication, with critical roles in cancer, the spread of
infection, and physiological processes such as stress, inflam-
mation, wound healing, coagulation, and angiogenesis.9 We
recently reported that circulating exosomes isolated from
LTxRs with AR or bronchiolitis obliterans syndrome (BOS)
contain DSA, lung SAgs, major histocompatibility complex
class II molecules, costimulatory molecules CD80 and CD86,
transcription factor NF-kB, CIITA, and 20S proteasome.10
However, the biological functions and fate of EVs released after
LTx remain unknown. The goal of this study is to identify,
compare, and contrast proteomic signatures in the circulating
EVs isolated from LTxRs diagnosed with AR, RVI, or BOS vs
stable LTxRs, using mass spectrometry to clarify the molecular
mechanisms underlying lung allograft rejection.
2. RESULTS AND DISCUSSION
2.1. EV Protein Cargo Characterization in LTxRs.
Proteomic analysis of circulating EVs identified a total of 2834
peptides mapping to 236 nonredundant proteins. Overall, 136
proteins (57.6%) were common to all conditions (Figure 1)
and 8, 24, 2, and 4 proteins were unique to LTxRs in the
stable, BOS, AR, and RVI groups, respectively. An average of
164 proteins was identified in BOS (n = 3) with an average of
78% mapping to ExoCarta. In patients with AR (n = 3), an
average of 128 proteins was identified and 79% were present in
ExoCarta. An average of 145 proteins was identified in RVI (n
= 3) and 76% were in ExoCarta. For stable patients (n = 5), an
average of 143 proteins was identified with 79% annotated in
ExoCarta. (Table 1). Eight proteins uniquely identified in EVs
from stable LTxRs (ACTR2, EFEMP1, IGKV1−16, IGKV1D-
39, IGLV2−23, GNL1, PFKP, and S100-A12; Figure 1 and
Table 2) are involved in the transport of small molecules,
signal transduction, hemostasis, and extracellular matrix
organization. Two proteins uniquely identified in AR
(CFHR2 and IGKV1−33; Figure 1 and Table 2) are
associated with immunoglobulin and complement regulation.
The 24 proteins uniquely identified in LTxRs with BOS
(ATP2A3, CANX, CD36, CPB2, ENDOD1, F9, GANAB,
GP1BB, HIST1H4A, HSPA5, IGHV1−3, IGKV3D-20,
IGLV4−60, ITGA6, ITGB1, MYH9, MYL6, PDIA3, PF4,
PSMA2, PSMA7, PTGS1, TTYH3, and YWHAZ; Figure 1 and
Table 2) are associated with immune activation, including
immunoglobulin synthesis, programmed cell death, and DNA
repair. EVs from LTxRs with RVI harbored 4 unique proteins
(GPX3, HSPG2, IGHD, and IGLV9−49; Figure 1 and Table
2) linked to macrophage and immune activation.
2.2. Differential Analysis of EV Proteomes from LTxR
Subgroups. Differential analysis across stable LTxRs and
those with BOS, AR, and RVI revealed significantly (p < 0.05,
log2 fold change (FC) > ±1) upregulated or downregulated
proteins listed in Table 3 and visualized on the volcano plots
(Figure 2). BOS showed an increase in the carboxypeptidase N
catalytic chain (CPN1, p = 0.01) and a decrease in the
polymeric immunoglobulin receptor (PIGR, p = 0.02), while
AR showed an increase in several complement proteins
including C3 (p = 0.006), C6 (p = 0.0009), C7 (p = 0.01),
CFI (p = 0.005), CFB (p = 0.03), CFH (p = 0.03), and C8B (p
= 0.04) and a decrease in immunoglobulin-associated proteins
(IGLV2-18 (p = 0.01), IGLV7-46 (p = 0.01), and IGKV6D-21
(p = 0.04)). EVs from LTxRs with RVI identified two
differentially abundant proteins: macrophage-stimulating pro-
tein (MST1) (increased, p = 0.01) and IGCL7 (immunoglo-
bulin lambda constant 7) (decreased, p = 0.04).
Unsupervised clustering (Supporting Information, Figure
S1) of the 35 significant differentially abundant proteins
showed that the AR patients have a very distinct abundance
profile of these proteins compared to the other LTxR
conditions while a wide heterogeneity persists between other
LTxR conditions. Details on proteins used for each pairwise
analysis are provided in Supporting Information, Table S1.
2.3. LTxR-Derived EVs Contain Distinct Functional
Signatures. Gene set enrichment analysis (GSEA) identified
pathways and biological processes enriched in stable LTxRs
and LTxRs with AR, BOS, or RVI (Figure 3). In LTxRs with
AR, upregulated proteins contributed to a positive enrichment
Figure 1. Venn diagram of proteins identified in extracellular vesicles
isolated from patients in 4 conditions after lung transplant.
Abbreviations: AR, acute rejection; BOS, bronchiolitis obliterans
syndrome; and RVI, respiratory viral infection.
Table 1. Total Protein Identifications in EVs from Patients
Post LTxa
group total peptides total proteins proteins mapped to ExoCarta (%)
BOS 2793 138 114 (83)
3245 190 145 (76)
3211 163 124 (76)
AR 2373 122 99 (81)
2636 137 103 (75)
2451 125 100 (80)
RVI 3190 161 126 (78)
2828 137 103 (75)
2867 137 103 (75)
stable 2547 135 108 (80)
3136 166 125 (75)
2788 142 102 (72)
2790 137 117 (85)
2824 135 108 (80)
aAbbreviations: EVs, extracellular vesicles; LTx, lung transplant; BOS,
bronchiolitis obliterans syndrome; AR, acute rejection; RVI,
respiratory viral infection.
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of 4 gene sets (hallmark coagulation, innate immune system,
regulation of intracellular transduction, and activation of
immune response). Downregulated proteins were associated
with a negatively enriched functional gene set (small molecule
metabolic process; Figure 3A).
Fifteen gene sets were significantly enriched in LTxRs with
BOS (Figure 3B). Twelve sets were negatively enriched in
LTxRs with BOS; of these, 2 gene sets are associated with
cellular death. The top 3 negatively enriched sets are associated
with catabolic processes. Of the 3 positively enriched sets, 2 are
associated with regulation of the extracellular matrix
(matrisome-associated and extracellular matrix regulators)
and the third is associated with complement system response
(lectin pathway).
In LTxRs with RVI, GSEA identified 10 positively and 2
negatively enriched gene sets, associated with upregulated and
downregulated proteins, respectively (Figure 3C). Four of the
positively enriched sets are associated with lipid metabolism
Table 2. Unique Proteins in Each LTx Conditiona
LTxR
group
uniprot
accession gene description
molecular
function biological role
# of
patients
BOS
(N = 3)
Q93084-4 ATP2A3 sarcoplasmic/endoplasmic reticulum calcium
ATPase 3
translocase calcium transport 1
P05556 ITGB1 integrin β-1 receptor cell adhesion 1
P16671-4 CD36 platelet glycoprotein 4 receptor cell adhesion 1
P23229-7 ITGA6 Integrin α-6 receptor cell adhesion 1
P35579 MYH9 myosin-9 actin binding cell adhesion 1
P02776 PF4 platelet factor 4 cytokine chemotaxis 1
O14818 PSMA7 proteasome subunit α type-7 hydrolase component of the 20S core
proteasome complex
1
P25787 PSMA2 proteasome subunit α type-2 hydrolase component of the 20S core
proteasome complex
1
P62805 H4C1 histone H4 DNA binding core component of nucleosome 1
Q14697 GANAB neutral α-glucosidase AB hydrolase glycan metabolism 1
P00740-2 F9 coagulation factor IX hydrolase hemostasis 1
P13224 GP1BB platelet glycoprotein Ib β chain protein binding hemostasis 1
Q96IY4 CPB2 carboxypeptidase B2 hydrolase hemostasis 1
A0A075B6I1 IGLV4−60 immunoglobulin lambda variable 4−60 antigen binding immunity 1
A0A0C4DH25 IGKV3D-
20
immunoglobulin kappa variable 3D-20 antigen binding immunity 1
A0A0C4DH29 IGHV1−3 immunoglobulin heavy variable 1−3 antigen binding immunity 1
Q9C0H2-3 TTYH3 protein tweety homolog 3 ion channel ion transport 1
P23219-4 PTGS1 prostaglandin G/H synthase 1 dioxygenase lipid metabolism 1
O94919 ENDOD1 endonuclease domain-containing 1 protein endonuclease
activity
platelet degranulation 1
P30101 PDIA3 protein disulfide-isomerase A3 isomerase protein folding 1
P11021 HSPA5 endoplasmic reticulum chaperone BiP chaperone protein folding and quality
control
1
P27824-3 CANX calnexin chaperone protein folding and quality
control
1
P60660-2 MYL6 myosin light polypeptide 6 motor protein regulatory light chain of myosin 1
P63104 YWHAZ 14-3-3 protein zeta/delta adapter protein signal transduction 1
AR
(N = 3)
P01594 IGKV1−33 immunoglobulin kappa variable 1−33 antigen binding immunity 1
P36980-2 CFHR2 complement factor H-related protein 2 protein binding regulation of complement
activation
1
RVI
(N = 3)
A0A0B4J1Y8 IGLV9−49 immunoglobulin lambda variable 9-49 antigen binding immunity 1
P01880 IGHD immunoglobulin heavy constant delta antigen binding immunity 1
P22352 GPX3 glutathione peroxidase 3 oxidoreductase cellular response to oxidative
stress
2
P98160 HSPG2 basement membrane-specific heparan sulfate
proteoglycan core protein
amyloid-β
binding
angiogenesis 1
stable
(N = 5)
P04432 IGKV1D-
39
immunoglobulin kappa variable 1D-39 antigen binding immunity 2
P01705 IGLV2−23 immunoglobulin lambda variable 2−23 antigen binding immunity 1
P04430 IGKV1−16 immunoglobulin kappa variable 1−16 antigen binding Immunity 1
P80511 S100-A12 Protein S100-A12 metal binding immunity 1
Q01813-2 PFKP ATP-dependent 6-phosphofructokinase, platelet
type
ATP binding glycolysis 1
P61160 ACTR2 actin-related protein 2 actin binding constituent of ARP2/3 complex 1
P36915-2 GNL1 guanine nucleotide-binding protein-like 1 GTPase activity signal transduction 1
Q12805-5 EFEMP1 EGF-containing fibulin-like extracellular matrix
protein 1
EGF and EGFR
binding
signal transduction 1
aProteins present in 3 out of 3 technical replicates for each patient were compared. Proteins unique to a LTx group are presented, with the number
of patients each protein was identified in. Functional information is taken from protein annotation in the Uniprot database.
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(regulation of the lipid metabolic process, cellular lipid
metabolic process, lipid metabolic process, and regulation of
lipid localization). The 2 negatively enriched sets are
associated with immune response (innate immune system
and defense response to bacterium).
Across the 3 GSEA analyses, only two enriched gene sets
were shared between LTxRs with rejection; the innate immune
system is positively enriched in the setting of AR and is
negatively enriched in LTxRs with RVI. Negative regulation of
cellular component organization is negatively enriched in
LTxRs with BOS and is positively enriched in LTxRs with RVI.
2.4. Validation of Key Proteins in Each Clinical
Condition Using Immunoblot. To validate our findings
by Western blot, we selected several differentially abundant
proteins (C3 for AR, CPN1 for BOS, and MST1 for RVI). C3
was present in EVs from AR samples, which are ∼2.3-fold
higher as compared to EVs from stable samples (Figure 4a,d).
CPN1 was present in 4.0-fold higher quantities in EVs from
BOS than stable (Figure 4b,e). MST1 was 7.0-fold increased in
RVI compared to stable patients (Figure 4c,f). Differential
abundance of MST1 in RVI, C3 in AR samples, and CPN1 in
BOS was statistically significant (p ≤ 0.005) compared to
stable. However, we have done Western blots of MV isolated
from normal and did not detect any of the key proteins what
we identified post LTx (collagen V and Kα1 tubulin).
We previously published our observation of increased levels
of donor HLA, lung SAgs, transcription factor NF-Kβ, CIITA,
and 20S proteasome in circulating exosomes of LTxRs with AR
and BOS.10,11 In the current study, we demonstrated that
circulating EVs from LTxRs with AR contained significantly
increased levels of immunoglobulin and complement regu-
latory proteins, along with coagulation factors and plasmi-
nogen, compared to stable LTxRs. A report by Naesens et al.12
showed that renal transplant biopsies classified as cellular
rejection contain B lymphocytes capable of producing
antibodies (Abs) against donor antigens, along with C3,
CD20, and peritubular deposition of C4D. In agreement, our
results also showed humoral-pathway activation in LTxRs
diagnosed with cellular AR. We demonstrated the upregulation
of proteins associated with complement, immunoglobulins,
coagulation, and inflammation in LTxRs with cellular rejection.
Complement activation is known to have a strong correlation
with tissue injury and antibody-mediated rejection,13 and our
results suggest that complement-mediated tissue injury can
occur even in patients diagnosed with cellular rejection.
Furthermore, our result raises the possibility that complement
proteins in circulating EVs can be markers to differentiate
cellular rejection with a mixed phenotype (i.e., cellular and
humoral) from only having a cellular phenotype.
Extracellular vesicles isolated from LTxRs with BOS showed
increased amounts of CPN1, a zinc metalloprotease with a
known protective function against vasoactive and inflammatory
peptides.14 CPN levels are associated with complement
activation; therefore, higher levels of CPN1 in LTxRs with
BOS indicate increased complement activation. EVs from
LTxRs with BOS also showed altered levels of PIGR. PIGR
binds and transports polymeric immunoglobulin A and
immunoglobulin M across the epithelial barrier to mucosal
surfaces.15 Studies have shown that gastroesophageal reflux
increases the risk of BOS after LTx.16 We therefore propose
that PIGR may be a contributing factor for gastroesophageal
reflux disease (GERD), increasing the risk of BOS.
Extracellular vesicles isolated from LTxRs with symptomatic
RVI (e.g., respiratory syncytial virus, coronavirus, rhinovirus,
and influenza virus) showed significantly increased levels of
MST1, a macrophage-stimulating protein also known as
hepatocyte growth factor-like protein, compared to stable
LTxRs.17 MST1/2 is a mediator of innate immune response18
against viruses, eliciting macrophage phagocytosis as well as
cytokines and production of reactive oxygen species.
Upregulation of MST1 in EVs isolated from LTxRs with
RVI suggests that circulating EVs can be involved in the
activation of innate immune responses, which leads to
increased cytokine and reactive oxygen species production
toward controlling the infection. MST1 is also likely to play an
important role in lung tissue regeneration after RVI, as
suggested by Narasaraju et al.19 Thus, our finding of increased
levels of MST1 in EVs from LTxRs with RVI strongly suggests
Table 3. Significant Differentially Abundant Proteins in EVs
of LTxRs: Significant Differentially Abundant Proteins (p <
0.05 and log2(FC) > ±1) in Each Rejection Condition
Compared to Stablea
LTxRs with AR vs stable LTxRs
gene names p-value p-Adj (BH) log2(FC)
C6 0.001 0.0834 1.312
AMBP 0.0025 0.055 1.295
FBLN1 0.0026 0.0767 1.169
ITIH4 0.003 0.1732 1.795
CFI 0.0054 0.0973 1.745
C3 0.0064 0.0808 1.443
APOC3 0.0077 0.0934 1.799
VWF 0.0103 0.1732 1.395
C7 0.0115 0.0371 1.492
CFB 0.0364 0.0543 1.055
CFH 0.0382 0.0543 1.116
ECM1 0.0419 0.1732 1.522
F11 0.0431 0.1732 1.372
ITIH1 0.044 0.1732 1.104
C8B 0.0477 0.1732 1.109
CLU 0.0001 0.1732 −1.247
VTN 0.0011 0.134 −1.451
GAPDH 0.0012 0.1732 −3.914
PON1 0.0036 0.0178 −1.805
KLKB1 0.0079 0.0834 −1.313
IGLV2-18 0.0179 0.1732 −2.568
IGLV7-46 0.0181 0.1732 −1.8
APOA1 0.02 0.0371 −1.162
IGLC7 0.0295 0.1279 −1.201
VTN 0.0303 0.0578 −3.215
IGLV1-40 0.0322 0.1732 −1.114
APOA2 0.035 0.1732 −1.412
IGHM 0.0353 0.1279 −1.421
ACTB 0.0361 0.1732 −2.068
IGKV6D-21 0.0445 0.1732 −2.414
TLN1 0.0477 0.0371 −3.413
LTxRs with BOS vs Stable LTxRs
CPN1 0.0141 0.945 1.134
PIGR 0.0243 0.945 −1.403
LTxRs with RVI vs Stable LTxRs
MST1 0.0109 0.865 1.363
IGLC7 0.0407 0.865 −1.324
aAbbreviations: EVs, extracellular vesicles; LTx, lung transplant;
LTxRs, lung transplant recipients, AR, acute rejection; BOS,
bronchiolitis obliterans syndrome; RVI, respiratory viral infection.
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that this protein may be involved in the repair of damaged lung
epithelium caused by a viral infection. Furthermore, we
propose that in LTxRs, MST1 contained in EVs can be used
as a protein signature specific to RVI and could be a useful
marker for the challenging differential diagnosis of RVI from
acute cellular rejection.
We are identifying proteins in the EV, which are diagnostic
for AR, BOS, and RVI. However, these samples were obtained
at the time of diagnosis. Further studies are needed to
determine the value of these proteins in the EV as a
noninvasive biomarker, which will require testing serial
samples from a larger cohort. Further, chronic rejection
following human LTx is now termed as chronic lung allograft
dysfunction, which consists of restrictive allograft syndrome
(RAS) and BOS. During this study, we have analyzed only
BOS but not RAS and therefore further analysis of EV from
RAS needs to be carried out to determine the potential value of
unique proteins that may be present in RAS, which may
provide further clues to the pathogenesis of RAS vs BOS.
The low number of LTxR specimens from which EVs were
characterized is a limitation of this study. This is particularly
true for LTxRs with AR, as our data suggest a mixed cellular
and humoral phenotype for the LTxRs with AR analyzed thus
far. Therefore, follow-up studies should include additional
LTxRs diagnosed either with cellular rejection or antibody-
mediated rejection. Another shortcoming of this study is that
we analyzed only rhinovirus, coronavirus, and metapneumo-
virus. Inclusion of LTxRs with other common infections
associated with increased risk for BOS (e.g., respiratory
syncytial virus and cytomegalovirus) should be considered in
future analysis. According to guidelines from the International
Society for Heart and Lung Transplantation, chronic lung
allograft dysfunction is classified as BOS or RAS, and our
analysis has been restricted only to BOS.24
3. CONCLUSIONS
The presence of unique proteins and their association with
pathways in the EVs isolated from plasma samples of LTxRs
with AR, BOS, and RVI provide important mechanistic
information about rejection after LTx. In summary, proteomic
findings from this study clearly demonstrate not only novel
mechanisms for rejection but also the potential of EV protein
cargo to distinguish different forms of AR (cellular vs humoral
vs mixed). Our results highlight the role of immunoglobulins
and complement proteins in BOS, which emphasizes the
importance of Abs in the pathogenesis of BOS. The abundance
Figure 2. Volcano plots of differentially abundant proteins in LTxRs. log2(FC) vs −log10(p-value) for (A) AR vs stable, (B) BOS vs stable, and (C)
RVI vs stable. Green dots (−log10(p-value) >1.301 and log2(FC) > ±1). Orange dots (log2(FC) > ±1). Blue (−log10(p-value) > 1.301).
Abbreviations: AR, acute rejection; BOS, bronchiolitis obliterans syndrome; and RVI, respirataory viral infection.
Figure 3. Significantly enriched GSEA-enriched (p-value <0.05)
terms from gene ontology biological processes (GOBP) associated
with the 3 described conditions vs stable LTxRs. (A) AR vs stable,
(B) BOS vs stable, and (C) RVI vs stable. Abbreviations: AR, acute
rejection; BOS, bronchiolitis obliterans syndrome; and RVI,
respiratory viral infection. The computed normalized enrichment
score shows GOBP terms that are increased (orange) or decreased
(blue).
ACS Omega http://pubs.acs.org/journal/acsodf Article
https://dx.doi.org/10.1021/acsomega.0c00859
ACS Omega 2020, 5, 14360−14369
14364
of MST1 in EVs from LTxRs with RVI suggests that MST1
can be a potential marker to differentiate RVI from AR.
The presence of immunoglobulin and complement proteins
in circulating EVs isolated from LTxRs with cellular AR
provides a means to differentiate cellular rejection from mixed
(i.e., cellular and humoral) rejection. The presence of
immunoglobulins in EVs from LTxRs with BOS suggests an
important role for Abs, both against DSA and lung-associated
SAgs, in the pathogenesis of BOS, as several studies have
demonstrated that development of DSA and Abs to lung SAgs
is an important risk factor for BOS after LTx.20−23 In addition,
validation using Western blots of several proteins (C3, CPN1,
and MST1), which are differentially present in LTxRs with AR,
BOS, and RVI, suggests that differentiating between acute/
chronic rejection and viral infection after LTx is possible using
this subset of protein markers.
4. MATERIALS AND METHODS
4.1. Patient Population. Lung transplant recipients at St.
Joseph’s Hospital and Medical Center in Phoenix, Arizona, and
from Washington University Medical School in St. Louis,
Missouri, were selected based on clinical diagnosis of AR, RVI
(rhinovirus, metapneumovirus, and coronavirus), BOS, and
stable per criterion established by ISHLT.24 This study was
approved by the Institutional Review Boards of St. Joseph’s
Hospital and Medical Center (IRB #PHXB16-0027-10-18),
and patient samples were collected after informed consent was
obtained.
4.2. Sample Collection. Blood samples were collected
from patients in acid citrate dextrose solution, and plasma was
isolated within 24 h of collection and stored at −80 °C. LTxR
demographics are summarized in Table 4.
4.3. EV Enrichment. Extracellular vesicles were isolated
from 500 μL of plasma by ultracentrifugation, as previously
described.25 Briefly, the samples were centrifuged at 2000 rcf
(20 min, 4 °C) followed by 2 cycles of centrifugation at 10 000
rcf (40 min, 4 °C). The supernatant was diluted with 0.5 mL of
phosphate-buffered saline (PBS) and spun for 100 000 rcf (120
min, 4 °C). EV pellets were resuspended in PBS. This final
centrifugation step was repeated, and the EV pellets were
recovered and stored at −80 °C. EV size distribution was
determined using NanoSight (Malvern Panalytical, Malvern,
United Kingdom; Figure 5), and EVs used in this report
ranged in size from 50 to 200 nm.26
4.4. Chemicals and Reagents. The chemicals and
solvents used were procured from Sigma-Aldrich (St. Louis,
MO) or Thermo Fisher Scientific (Waltham, MA). All
chemicals were analytical reagent grade. Formic acid and
solvents were liquid chromatography−mass spectrometry
(LC−MS/MS) grade. Halt protease and phosphatase-inhibitor
cocktail (100×) was obtained from Thermo Fisher Scientific
(Waltham, MA). Sequencing-grade enzymes were purchased
from Promega (Madison, WI).
Figure 4.Western blots of significantly differential proteins (a) C3, (b) MST1, and (c) CPN1 in stable, AR, BOS, and RVI samples from exosomes
from LTxRs. Densitometry of Western blots (d) C3, (e) MST1, and (f) CPN1. CD9 was used as an internal control for exosomes. The presented
data are representative of at least 3 independent experiments. The C3, CPN1, and MST1 levels were normalized to CD9 levels and are shown as
relative levels. Data are shown as mean ± standard deviation (SD). p-values were calculated using a two-tailed unpaired Student’s t-test. (***p <
0.005). Abbreviation: ST, stable; AR, acute rejection; BOS, bronchiolitis obliterans syndrome; and RVI, respiratory viral infection.
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4.5. Protein Extraction and Digestion. Pelleted EVs
were thawed and proteins were extracted in 250 μL of 25 mM
ammonium bicarbonate buffer (NH4HCO3), supplemented
with 1% sodium deoxycholate, 1× halt protease, and
phosphatase-inhibitor cocktail. Samples were lysed by
sonication for 1 min, followed by centrifugation at 21 000 rcf
(10 min, 4 °C) to pellet any debris. The supernatant was
transferred to 10 kD Amicon Ultrafilters (Sigma-Aldrich, St
Louis, MO) to perform filter-aided sample preparation for
shotgun proteomic analysis.27,28 Briefly, extracted proteins
were denatured with 8 M urea, reduced in 10 mM
dithiothreitol, and alkylated in 50 mM iodoacetamide. Samples
were subjected to a buffer exchange in 50 mM NH4HCO3,
followed by overnight digestion using trypsin at a 1:50 enzyme
to protein ratio at 37 °C. Peptides were extracted from the
filter at 14 000 rcf, and the flow-through was vacuum-dried and
stored at −80 °C until LC−MS/MS analysis was performed.
4.6. LC−MS/MS Analysis. Tryptic peptides were recon-
stituted in 0.1% formic acid and quantified by the
bicinchoninic acid assay for LC−MS/MS analysis on an
Orbitrap Fusion Lumos Tribrid (Thermo, Waltham, MA)
interfaced with a nanoAcquity UPLC system (Waters, Milford,
MA). For each sample acquired in technical triplicates, 800 ng
of peptides was first loaded on a trapping column (Acquity
UPLC M-Class Trap, two-dimensional (2-D) Symmetry C18,
100 Å pore size, 5 μm particle size, 20 mm length) and washed
for 10 min with 99.5% Solvent A (0.1% formic acid in water)
and 0.5% solvent B (0.1% formic acid in acetonitrile) at a flow
rate of 7.5 μL/min. The trapped peptides were transferred to
an analytical column (Acquity UPLC M-Class Peptide BEH
C18, 130 Å pore size, 1.7 μm particle size, 100 mm length) and
eluted at a flow rate of 500 nL/min using the following
gradient: 3−7% B in 1 min, 7−25% B in 25 min, 25−45% B in
10 min, 45−90% B in 0.5 min, 90% B for 1 min, back to initial
condition in 0.5 min, and re-equilibration for 10 min. Data-
dependent acquisition was performed in Top Speed mode with
a duty cycle of 3 s and the following parameters: spray voltage
of 1900 V, ion-transfer tube temperature of 275 °C, survey
scan in the Orbitrap at a resolution of 120 K at 200 m/z, scan
range of 400−1500 m/z, AGC target of 2E5, and maximum
ion injection time of 50 ms. Every parent scan was followed by
a daughter scan using high-energy collision dissociation of top
abundant peaks and detection in the ion trap with following
settings: quadrupole isolation mode, isolation window at 1.4
m/z, AGC target of 5E3 with maximum ion injection time of
50 ms, and high-energy collision energy of 35%. Dynamic
exclusion was set to 60 s.
4.7. Data Analysis. Mass spectra were matched to the
Homo sapiens database (2017, SwissProt/UniProtKB) using
the Andromeda search engine (MaxQuant v1.6.1.0)29 with a
false discovery rate (FDR) <1%, allowing up to 2 missed
cleavages from trypsin. All other MaxQuant settings were set to
default. Cysteine carbamidomethylation was set as a fixed
modification, and variable modifications of N-terminus
acetylation and methionine oxidation were allowed. The
peptides were identified using the match between runs feature
enabled, and protein intensities were computed using the
MaxQuant label-free quantitation (LFQ) algorithm. Iterative
rank order normalization (IRON)30 was used to normalize
LFQ intensities across all samples. For each patient, intensities
were averaged if the protein was identified in 3 out of 3
technical replicates, otherwise the protein was removed from
that patient. Protein intensity was log2-transformed, and fold
change for each protein was calculated between the stable
LTxR and each of the three rejection groups. Proteins
annotated by MaxQuant as hits to the reverse database (n =
6 proteins), potential contaminants (n = 19 proteins), or
without a unique peptide (n = 3 proteins) were not included
for differential analysis. Statistical significance of the change in
protein abundance between each pairwise analysis (stable
LTxR vs each of the three rejection groups) was determined
using Student’s t-test. A Benjamini−Hochberg test for multiple
corrections was also calculated. Proteins with a log2(fold
change) > ±1, corresponding to a 2-fold change from the
stable, and a t-test p-value <0.05 were deemed significantly
differentially abundant. Proteins were annotated using the
ExoCarta reference database.31 To identify enriched processes
and pathways in each rejection condition compared to stable
Table 4. Demographic Characteristics of 14 Lung
Transplant Recipientsa
variable N (%)
time of sample
collection
mean age, years ± SD 50.3 ± 12.2
male sex 7 (50)
white race 14 (100)
bilateral LTx 14 (100)
post-LTx diagnosis
BOS 3 (21) 1.5−2.0 years
AR 3 (21) 6 months
RVI 3 (21) 12−36 months
stable 5 (36) 12−36 months
reason for LTx by post-LTx
diagnosis
BOS
IPF 3/3 (100)
AR
COPD 1/3 (33)
IPF 2 (67)
RVI
COPD 2/3 (67)
IPF 1/3 (33)
stable
COPD 3/5 (60)
IPF 2/5 (20)
aAbbreviations: LTx, lung transplant; BOS, bronchiolitis obliterans
syndrome; AR, acute rejection; RVI, respiratory viral infection; IPF,
idiopathic pulmonary fibrosis; COPD, chronic obstructive pulmonary
disease.
Figure 5. Representative image of size determination of exosomes
using NanoSight.
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LTxRs, each protein was ordered by ranking score (RS =
−log10 (p-value)* ± 1, where the directionality matches the
fold change) from highest to lowest. Functional enrichment
analysis was performed using GSEA against the Gene
Ontology Resource (downloaded April 2019).32
4.8. Western Blots. Extracellular vesicles isolated with
ultracentrifugation25 were lysed using radioimmunoprecipita-
tion assay buffer containing protease inhibitor cocktails.
Protein was estimated using the bicinchoninic acid assay.
Western blot was performed to validate the signatures
identified by mass spectrometry. Briefly, 30 μg of protein
from EVs was resolved via polyacrylamide gel electrophoresis,
and the proteins were transferred into a poly(vinylidene
difluoride) membrane. The membrane was blocked with 5%
nonfat milk in 1× PBS and was probed with Abs to C3
(Abcam, anti-rabbit), CPN1 (Abcam, anti-rabbit), MST1 (Cell
Signaling Technology, anti-rabbit), and CD9 (Biolegend, anti-
mouse). Secondary Abs conjugated with horseradish perox-
idase were used for detection. The blots were washed with
PBS-Tween (Thermo Fisher Scientific), developed using the
chemiluminescent horseradish peroxidase substrate (Amer-
sham ECL Western Blotting Detection Kit), and exposed using
an Odyssey CLx Imaging System (LI-COR Biosciences,
Lincoln, NE).
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(28) Wisńiewski, J. R.; Zougman, A.; Nagaraj, N.; Mann, M.
Universal sample preparation method for proteome analysis. Nat.
Methods 2009, 6, 359−362.
(29) Cox, J.; Mann, M. MaxQuant enables high peptide
identification rates, individualized p.p.b.-range mass accuracies and
proteome-wide protein quantification. Nat. Biotechnol. 2008, 26,
1367−1372.
(30) Welsh, E. A.; Eschrich, S. A.; Berglund, A. E.; Fenstermacher,
D. A. Iterative rank-order normalization of gene expression microarray
data. BMC Bioinf. 2013, 14, No. 153.
(31) Keerthikumar, S.; Chisanga, D.; Ariyaratne, D.; Al Saffar, H.;
Anand, S.; Zhao, K.; Samuel, M.; Pathan, M.; Jois, M.; Chilamkurti,
N.; Gangoda, L.; Mathivanan, S. ExoCarta: A Web-Based Compen-
dium of Exosomal Cargo. J. Mol. Biol. 2016, 428, 688−692.
(32) Subramanian, A.; Tamayo, P.; Mootha, V. K.; Mukherjee, S.;
Ebert, B. L.; Gillette, M. A.; Paulovich, A.; Pomeroy, S. L.; Golub, T.
R.; Lander, E. S.; Mesirov, J. P. Gene set enrichment analysis: a
knowledge-based approach for interpreting genome-wide expression
profiles. Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 15545−15550.
ACS Omega http://pubs.acs.org/journal/acsodf Article
https://dx.doi.org/10.1021/acsomega.0c00859
ACS Omega 2020, 5, 14360−14369
14369
